Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 2/20 | 0.36 |
| ▸ | CNR2 | P34972 | 2/20 | 0.36 |
| ▸ | P2RX7 | Q99572 | 14/20 | 0.36 |
| ▸ | IL1B | P01584 | 13/20 | 0.36 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.33 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.33 |
| ▸ | TGFBR2 | P37173 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12743220 | 0.86 | CDK9 (0.36) | CNR1CNR2P2RX7IL1BPIK3CA | |
| SCHEMBL1614564 | 0.85 | MAP3K14 (0.36) | CNR1CNR2P2RX7IL1B | |
| SCHEMBL1614565 | 0.85 | MAP3K14 (0.36) | CNR1CNR2P2RX7IL1B | |
| SCHEMBL12743744 | 0.82 | CNR2 (0.35) | CNR1CNR2ALOX5AP | |
| SCHEMBL12743904 | 0.81 | CNR2 (0.37) | CNR1CNR2 | |
| SCHEMBL12743900 | 0.80 | DYRK1A (0.45) | P2RX7IL1BALOX5AP | |
| SCHEMBL12743739 | 0.79 | GRIN2B (0.42) | — | |
| SCHEMBL12743917 | 0.78 | KDM4C (0.33) | P2RX7IL1BPIK3CA | |
| SCHEMBL12743790 | 0.78 | ICMT (0.34) | — | |
| SCHEMBL12742516 | 0.78 | MAP4K1 (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110086834-A1 | ALKYNYL ALCOHOLS AS KINASE INHIBITORS | AMGEN INC. (US) | 2011-04-14 | — | — | US | disclosed |
| WO-2009158011-A1 | ALKYNYL ALCOHOLS AS KINASE INHIBITORS | AMGEN INC. (US) | 2009-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110086834-A1 | ALKYNYL ALCOHOLS AS KINASE INHIBITORS | NFKBIA, MAP3K1, MAP3K2 | CNR1 1667/4885CNR2 1549/4885P2RX7 3590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.